Trivium Point Advisory LLC Decreases Stake in CME Group Inc. (NASDAQ:CME)

Key Points

• Trivium Point Advisory LLC reduced its shareholding in CME Group by 15.4%, now holding 12,930 shares valued at approximately $3.43 million.
• Several institutional investors, including Vanguard Group and Price T Rowe Associates, have increased their stakes in CME Group, reflecting strong institutional interest.
• CME Group recently announced a quarterly dividend of $1.25 per share, with a yield of 1.8%, and reported earnings exceeding analysts' estimates for the previous quarter.

Trivium Point Advisory LLC reduced its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 15.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,930 shares of the financial services provider's stock after selling 2,360 shares during the period. Trivium Point Advisory LLC's holdings in CME Group were worth $3,430,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in CME Group by 89.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock valued at $1,923,047,000 after purchasing an additional 3,921,278 shares during the period. GQG Partners LLC raised its position in CME Group by 7,676.3% in the first quarter. GQG Partners LLC now owns 2,205,041 shares of the financial services provider's stock valued at $584,975,000 after purchasing an additional 2,176,685 shares during the period. GAMMA Investing LLC raised its position in CME Group by 32,941.0% in the first quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock valued at $493,144,000 after purchasing an additional 1,853,261 shares during the period. Nuveen LLC purchased a new stake in CME Group in the first quarter valued at approximately $218,842,000. Finally, Egerton Capital UK LLP raised its position in CME Group by 79.4% in the first quarter. Egerton Capital UK LLP now owns 1,730,194 shares of the financial services provider's stock valued at $459,003,000 after purchasing an additional 765,773 shares during the period. 87.75% of the stock is currently owned by institutional investors and hedge funds.

CME Group Trading Down 0.3%

CME stock traded down $0.78 during midday trading on Friday, hitting $273.92. The stock had a trading volume of 2,055,786 shares, compared to its average volume of 2,086,143. The firm has a market cap of $98.72 billion, a PE ratio of 26.52, a price-to-earnings-growth ratio of 4.86 and a beta of 0.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. CME Group Inc. has a 12-month low of $204.16 and a 12-month high of $290.79. The company's 50-day moving average price is $275.52 and its 200 day moving average price is $267.37.

CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.91 by $0.05. CME Group had a net margin of 58.48% and a return on equity of 14.60%. The company had revenue of $1.69 billion during the quarter, compared to analysts' expectations of $1.68 billion. During the same period in the previous year, the company earned $2.56 EPS. The business's quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts predict that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Tuesday, September 9th will be paid a dividend of $1.25 per share. The ex-dividend date of this dividend is Tuesday, September 9th. This represents a $5.00 annualized dividend and a dividend yield of 1.8%. CME Group's payout ratio is currently 48.40%.

Insider Activity at CME Group

In other news, Director Phyllis M. Lockett sold 1,060 shares of the business's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $277.88, for a total transaction of $294,552.80. Following the completion of the sale, the director directly owned 3,108 shares of the company's stock, valued at $863,651.04. The trade was a 25.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Shepard purchased 256 shares of the firm's stock in a transaction that occurred on Wednesday, June 25th. The shares were acquired at an average cost of $270.53 per share, with a total value of $69,255.68. Following the completion of the transaction, the director owned 258,196 shares in the company, valued at $69,849,763.88. This trade represents a 0.10% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 2,450 shares of company stock worth $676,663. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CME has been the topic of a number of research analyst reports. Oppenheimer boosted their target price on CME Group from $300.00 to $303.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. UBS Group reaffirmed a "neutral" rating and set a $305.00 price objective on shares of CME Group in a research report on Thursday, July 24th. Barclays set a $298.00 price objective on CME Group and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Erste Group Bank lowered CME Group from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Keefe, Bruyette & Woods upped their price objective on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, CME Group presently has a consensus rating of "Hold" and a consensus price target of $261.93.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.